A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion

Journal of Thrombosis and Thrombolysis

Volumn 24, Issue 1, 2007, Pages 1-5

  Verhamme, Peter ^a   Goossens, Godelieve ^a   Maleux, Geert ^a   Collen, Désiré ^a   Stas, Marguerite ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Catheter; Occlusion; Staphylokinase; Thrombolysis

Indexed keywords

STAPHYLOKINASE; UROKINASE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BOLUS INJECTION; CATHETER REMOVAL; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL;

ADULT; AGED; CATHETERS, INDWELLING; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HUMANS; METALLOENDOPEPTIDASES; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; SAFETY; THROMBOSIS;

EID: 34249695841     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-0006-4     Document Type: Article

References (12)

1. Lewis CA, Allen TE, Burke DR et al (2003) Quality improvement guidelines for central venous access. J Vasc Interv Radiol 14(9 Pt 2):S231-S235
2. Goossens GA, Vrebos M, De Wever I, Stas M (2004) Vacutainer filling time through subcutaneous venous access devices. J Vasc Access 5(4):154-160
3. Haire WD, Atkinson JB, Stephens LC, Kotulak GD (1994) Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: A double-blinded, randomized trial. Thromb Haemost 72(4):543-547
4. Svoboda P, Barton RP, Barbarash OL et al (2004) Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: A multiple-center, international trial. Crit Care Med 32(10):1990-1996
5. Semba CP, Deitcher SR, Li X, Resnansky L, Tu T, McCluskey ER (2002) Treatment of occluded central venous catheters with alteplase: Results in 1,064 patients. J Vasc Interv Radiol 13(12):1199-1205
6. Haire WD, Deitcher SR, Mullane KM et al (2004) Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial. Thromb Haemost 92(3):575-582
7. Collen D, Lijnen HR. (1994) Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood 84(3):680-686
8. Collen D, Vanderschueren S, Van De WF (1996) Fibrin-selective thrombolytic therapy with recombinant staphylokinase. Haemostasis 26(Suppl 4):294-300
9. Heymans S, Vanderschueren S, Verhaeghe R et al (2000) Outcome and one year follow-up of intra-arterial staphylokinase in 191 patients with peripheral arterial occlusion. Thromb Haemost 83(5):666-671
10. Vanderschueren S, Dens J, Kerdsinchai P et al (1997) Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J 134(2 Pt 1):213-219
11. Collen D, Stockx L, Lacroix H, Suy R, Vanderschueren S (1997) Recombinant staphylokinase variants with altered immunoreactivity. IV: identification of variants with reduced antibody induction but intact potency. Circulation 95(2):463-472
12. Haire WD (2001) Techniques in dosing for thrombolysis of occluded central venous catheters. Tech Vasc Interv Radiol 4(2):127-130